Director Bhanji Muna sold Veracyte ($VCYT) shares once for $122 thousand on June 13, 2025, ranking 9,280th among over 11,600 insiders. The director also sold Cytokinetics ($CYTK) shares once for $43 thousand on May 15, 2025 (10,539th rank) and Intellia Therapeutics ($NTLA) shares once for $2.3 thousand on April 29, 2025 (11,488th rank). These sales are well below the insider average of nearly 8.6 million dollars across 6 transactions. No open market purchases in the last year.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 18, 2025 | ARDELYX, INC. | $ARDX | Bhanji Muna | Director | A | Stock Option (Right to Buy) | 54059 | $0.00 | 54,059.0000 | 238,356,222 | 9999.99% | 0.02% |
| June 18, 2025 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | A | Common Stock | 9321 | $0.00 | 39,310.0000 | 78,163,217 | 31.08% | 0.01% |
| June 18, 2025 | ARDELYX, INC. | $ARDX | Bhanji Muna | Director | A | Common Stock | 41551 | $0.00 | 137,353.0000 | 238,356,222 | 43.37% | 0.02% |
| June 13, 2025 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 4589 | $26.67 | 29,989.0000 | 78,163,217 | 13.27% | 0.01% |
| June 11, 2025 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | A | Common Stock | 8000 | $0.00 | 27,203.0000 | 103,517,460 | 41.66% | 0.01% |
| June 11, 2025 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | A | Stock Option (right to buy) | 11450 | $0.00 | 11,450.0000 | 103,517,460 | 9999.99% | 0.01% |
| May 15, 2025 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | S | Common Stock | 1454 | $29.73 | 23,510.0000 | 118,410,689 | 5.82% | 0.00% |
| May 14, 2025 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Common Stock | 7333 | $0.00 | 24,964.0000 | 118,410,689 | 41.59% | 0.01% |
| May 14, 2025 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Non-Qualified Stock Option (Right to Buy) | 10880 | $0.00 | 10,880.0000 | 118,410,689 | 9999.99% | 0.01% |
| April 29, 2025 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | S | Common Stock | 265 | $8.50 | 19,203.0000 | 103,517,460 | 1.36% | 0.00% |
| Jan. 29, 2025 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | S | Common Stock | 265 | $9.97 | 19,468.0000 | 0 | 1.34% | 0.00% |
| June 14, 2024 | ARDELYX, INC. | $ARDX | Bhanji Muna | Director | A | Stock Option (Right to Buy) | 40243 | $0.00 | 40,243.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2024 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | A | Common Stock | 11473 | $0.00 | 34,578.0000 | 72,644,487 | 49.66% | 0.02% |
| June 12, 2024 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | A | Stock Option (right to buy) | 11515 | $0.00 | 11,515.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Not found | A | Common Stock | 7737 | $0.00 | 19,733.0000 | 0 | 64.50% | 0.00% |
| June 10, 2024 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 3870 | $20.32 | 23,105.0000 | 72,644,487 | 14.35% | 0.01% |
| June 10, 2024 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | S | Common Stock | 2000 | $52.07 | 17,631.0000 | 0 | 10.19% | 0.00% |
| May 28, 2024 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 1539 | $21.00 | 26,975.0000 | 72,644,487 | 5.40% | 0.00% |
| May 15, 2024 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Non-Qualified Stock Option (Right to Buy) | 3636 | $0.00 | 3,636.0000 | 0 | 9999.99% | 0.00% |
| May 15, 2024 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Common Stock | 5600 | $0.00 | 19,631.0000 | 0 | 39.91% | 0.00% |
| Oct. 31, 2023 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Director | S | Common Stock | 265 | $23.90 | 11,996.0000 | 0 | 2.16% | 0.00% |
| July 31, 2023 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Director | S | Common Stock | 265 | $42.33 | 12,261.0000 | 0 | 2.12% | 0.00% |
| July 6, 2023 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Director | S | Common Stock | 1867 | $39.30 | 12,526.0000 | 0 | 12.97% | 0.00% |
| July 7, 2023 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | S | Common Stock | 2000 | $34.12 | 14,031.0000 | 0 | 12.48% | 0.00% |
| June 16, 2023 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 5793 | $26.42 | 28,614.0000 | 71,549,204 | 16.84% | 0.01% |
| June 16, 2023 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 100 | $27.09 | 28,514.0000 | 71,549,204 | 0.35% | 0.00% |
| June 14, 2023 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Director | A | Common Stock | 4425 | $0.00 | 14,393.0000 | 0 | 44.39% | 0.00% |
| June 14, 2023 | Intellia Therapeutics, Inc. | $NTLA | Bhanji Muna | Director | A | Stock Option (right to buy) | 6473 | $0.00 | 6,473.0000 | 0 | 9999.99% | 0.00% |
| June 9, 2023 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | A | Common Stock | 9674 | $0.00 | 34,407.0000 | 71,549,204 | 39.11% | 0.01% |
| May 30, 2023 | VERACYTE, INC. | $VCYT | Bhanji Muna | Director | S | Common Stock | 1539 | $25.91 | 24,733.0000 | 71,549,204 | 5.86% | 0.00% |
| May 10, 2023 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Common Stock | 5000 | $0.00 | 16,031.0000 | 0 | 45.33% | 0.00% |
| May 10, 2023 | CYTOKINETICS INC | $CYTK | Bhanji Muna | Director | A | Non-Qualified Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |